By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
ICCNICCNICCN
  • Home
  • Conferences
  • Events
  • Media
  • Publications
  • Resources
    • NCCN
    • ASCO
    • Hematology
Reading: SOHO 2025 Meeting
Sign In
Font ResizerAa
Font ResizerAa
ICCNICCN
  • Home
  • Conferences
  • Events
  • Media
  • Publications
  • Resources
Search
  • Home
  • Conferences
  • Events
  • Media
  • Publications
  • Resources
    • NCCN
    • ASCO
    • Hematology

Trending →

T-DXd Plus Pertuzumab Receives FDA Approval, Shifting the Frontline HER2-Positive Paradigm

By MedOnc2
December 15, 2025

FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA2-Mutated mCSPC

By MedOnc2
December 15, 2025

FDA Approves Durvalumab for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma

By MedOnc2
December 15, 2025

FDA Grants Traditional Approval to Pirtobrutinib (Jaypirca®) for CLL/SLL

By MedOnc2
December 15, 2025

Enfortumab Vedotin + Pembrolizumab for Muscle-Invasive Bladder Cancer (MIBC)

By MedOnc2
November 22, 2025
Login Sign In
Follow US
© ICCN All Rights Reserved.
Conferences

SOHO 2025 Meeting

MedOnc2
Last updated: August 13, 2025 12:43 am
By MedOnc2
Share
1 Min Read
SHARE

The Society of Hematologic Oncology (SOHO) 2025 Annual Meeting will be held September 3-6, 2025, in Houston, Texas, at the George R. Brown Convention Center. This hybrid event will offer both in-person and virtual participation. The meeting will focus on the latest advancements in the treatment of hematologic malignancies.

Dates: 

September 3-6, 2025. 

Location: 

George R. Brown Convention Center in Houston, Texas. 

Format: 

Hybrid (in-person and virtual). 

Theme: 

“Unleashing AI, Genomics, Targets, and Immune Engineering”

Registration:

http://soho.click/2025

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Tumblr Reddit Email Copy Link Print

Recent Posts

  • T-DXd Plus Pertuzumab Receives FDA Approval, Shifting the Frontline HER2-Positive Paradigm
  • FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA2-Mutated mCSPC
  • FDA Approves Durvalumab for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
  • FDA Grants Traditional Approval to Pirtobrutinib (Jaypirca®) for CLL/SLL
  • Enfortumab Vedotin + Pembrolizumab for Muscle-Invasive Bladder Cancer (MIBC)

Recent Comments

No comments to show.

You Might Also Like ↷

ASH 2025 Annual Meeting

August 10, 2025

ESMO Congress 2025

August 11, 2025
Interactive Cancer Care Network

Powered By Designjoom-Empowering Brands since 2010